What is the Share Price of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd share price is ₹1,394.90 As on 09 May, 2025|10:14

Home
>
Stocks
>
Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd Share Price

Q: What is the Market Cap of Glenmark Pharmaceuticals Ltd?

The Market Cap of Glenmark Pharmaceuticals Ltd is ₹40,026 As on 09 May, 2025|10:14

Q: What is PE Ratio of Glenmark Pharmaceuticals Ltd?

The P/E ratio of Glenmark Pharmaceuticals Ltd is 17.4 As on 09 May, 2025|10:14

Q: What is PB Ratio of Glenmark Pharmaceuticals Ltd?

The PB ratio of Glenmark Pharmaceuticals Ltd is 4.67 As on 09 May, 2025|10:14

₹ 1,394.90 -24.00 (-1.69%)
Updated on 09-05-2025 10:14 AM

Stock Rating

Pros 0

Cons 6

Option Chain

Glenmark Pharmaceuticals Ltd Price Performance

Day's Low
₹1,385

Day's High
₹1,410

₹ 1,394.90

52-w low
₹985.2

52-w high
₹1,830.95

1,394.90

Day's open
₹1,395
Previous close
₹1,418.90
VWAP
₹1,397.63
Lower price band
₹1,277.10
Upper price band
₹1,560.70

Today's Market Action

The last traded share price of Glenmark Pharmaceuticals Ltd was 1,394.90 down by -1.69% on the NSE. Its last traded stock price on BSE was 1,394 down by -1.54%. The total volume of shares on NSE and BSE combined was 81,845 shares. Its total combined turnover was Rs 11.44 crores.

Glenmark Pharmaceuticals Ltd Medium and Long Term Market Action

Glenmark Pharmaceuticals Ltd hit a 52-week high of 1,830.95 on 15-10-2024 and a 52-week low of 985.2 on 16-05-2024. The stock price of Glenmark Pharmaceuticals Ltd is up by 4% over the last one month. It is up by 36.75% over the last one year. Don't forget to check the full stock price history in the table below.

Glenmark Pharmaceuticals Ltd Fundamentals

Market Cap (Cr): 40026
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Glenmark Pharmaceuticals Ltd Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Glenmark Pharmaceuticals Ltd Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Glenmark Pharmaceuticals Ltd

Data not available.

Glenmark Pharmaceuticals Ltd FAQ's

What is Share Price of Glenmark Pharmaceuticals Ltd?

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

What is PE Ratio of Glenmark Pharmaceuticals Ltd?

What is PB Ratio of Glenmark Pharmaceuticals Ltd?

What is the CAGR of Glenmark Pharmaceuticals Ltd?

How to Buy Glenmark Pharmaceuticals Ltd Share?

Can I buy Glenmark Pharmaceuticals Ltd from Samco?

How do I buy Glenmark Pharmaceuticals Ltd from Samco?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

No Data Available

Cons

Low Sustainable RoE
The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
Low Return on Capital Employed
The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
Poor Cash Flow Conversion
The business has very poor cash conversion ratio of only -17.30% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
Low Interest Coverage
The company has a very low Interest coverage ratio of 2.32 times which implies that a large portion of operating profits are getting attributed to payment of interest to debtholders. This leaves lower earnings and cash flows for equity shareholders which is negative for returns.
Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 132 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.

Valuation Analysis

Margin of safety
(09/05/2025)

104

Margin of Safety Index: High

84.21%

84.21% People are bullish about Glenmark Pharmaceuticals Ltd

15.79%

15.79 % People are bearish about Glenmark Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %